RecruitingPhobia, Social
Investigating the Effects of Cannabidiol on Social Anxiety Disorder
Eligible age
18–55 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
Sponsor: Massachusetts Institute of Technology
You may qualify if…
- ✓ Ability and willingness to provide written informed consent.
- ✓ Sufficiently fluent in English to participate in the trial.
- ✓ Between 18-55 years of age (inclusive).
- ✓ Right-hand dominant.
- ✓ Current medications are stable for past 30 days (no changes to dose or frequency).
- ✓ Negative result on pregnancy test (if female).
- ✓ Negative result on urine drug screening.
- ✓ Liebowitz Social Anxiety Scale (LSAS ≥ 60).
You may not qualify if…
- ✕ History of bipolar disorder, schizophrenia, psychosis, delusional disorders.
- ✕ History of eating disorder within past 6 months.
- ✕ History of any traumatic brain injury.
- ✕ Currently diagnosed with diabetes mellitus.
- ✕ Presence of severe medical illness that would prevent completion of study procedures.
- ✕ Presence of significant neurological illness or cognitive dysfunction (e.g.; seizures, dementia).
- ✕ History of substance use disorder within past 6 months (other than nicotine and caffeine).
- ✕ Use of any cannabis-containing products in past 30 days (CBD or THC).
Where it's recruiting
Massachusetts
Cambridge
Source: ClinicalTrials.gov · NCT05649059 · last updated 2026-08-11